Differential ability of tumor-unique and cross-reactive antigen(s) on two murine hepatoma cell lines to induce Lyt-1+2- T cells responsible for in vivo protective immunity.
Differential ability of tumor-unique and cross-reactive antigen(s) on two murine hepatoma cell lines to induce Lyt-1+2- T cells responsible for in vivo protective immunity.
复制标题
两种小鼠肝癌细胞系上肿瘤独特和交叉反应抗原诱导负责体内保护性免疫的 Lyt-1 2- T 细胞的差异能力。
DOI：
--
复制
发表时间：
1987
期刊：
影响因子：
--
通讯作者：
S. Kato
中科院分区：
文献类型：
--
作者：
J. Shima;T. Yoshioka;A. Kosugi;M. Ogata;H. Fujiwara;T. Hamaoka;S. Ueda;S. Kato
以肿瘤交叉反应决定簇(S)为对照，研究了肿瘤特异性决定簇(S)在两种同基因小鼠肝癌细胞诱导体内保护性免疫中的作用。腹腔注射诱导C3H/He小鼠的痘苗反应性辅助性T细胞用活的痘苗病毒接种痘苗病毒，然后用痘苗病毒感染的同基因MH134或MH129肿瘤细胞免疫，可产生有效的抗MH134或-MH129抗体，并产生体内保护性免疫。两种抗体均不与其他同基因浆细胞瘤或纤维肉瘤细胞反应，但与其他肝癌细胞有明显的交叉反应，与用于免疫的肿瘤细胞也有较强的反应。抗MH134和-MH129抗血清被相应的肝癌细胞吸收后，它们与相应的肝癌细胞和其他肝癌细胞的反应性都消失了。相反，这些抗血清与其他肿瘤细胞的吸收导致它们与其他肝癌细胞的交叉反应丧失，但不会失去它们对相应肝癌细胞的特异性反应。虽然在这些血肿系统中，上述免疫方案可在体内诱导保护性免疫并产生抗体，但通过Winn实验观察到的体内免疫是由Lyt-1+2-T细胞介导的，并且对每种类型的肝癌细胞都是特异的。这些结果表明，这两种类型的肝癌细胞携带两种抗原决定簇，一种是每个肝癌所特有的，另一种是与其他肝癌细胞发生交叉反应的。
The role of the tumor-unique determinant(s) on two syngeneic murine hepatoma cells in inducing in vivo protective immunity was investigated in comparison with that of the tumor-cross-reactive determinant(s). Induction of vaccinia-reactive helper T cells in C3H/He mice by intraperitoneal (i.p.) inoculation of viable vaccinia virus and then immunization with vaccinia-infected syngeneic MH134 or MH129 tumor cells resulted in the production of potent anti-MH134 or -MH129 antibody as well as the generation of in vivo protective immunity. Neither antibody reacted with other syngeneic plasmacytoma or fibrosarcoma cells, but both cross-reacted appreciably with the other hepatoma cells as well reacted strongly as with the tumor cells used for immunization. The absorptions of anti-MH134 and -MH129 antisera with the respective hepatoma cells abolished their reactivities with both the corresponding hepatoma cells and the other hepatoma cells. In contrast, the absorption of these antisera with the other tumor cells resulted in loss of their cross-reactivities with the other hepatoma cells, but not loss of their specific reactivity to the respective hepatoma cells. Although in these hematoma systems, the above-mentioned immunization protocol resulted in in vivo induction of protective immunity and generation of antibodies, in vivo immunity as observed by Winn assays was mediated by Lyt-1+2- T cells and was specific for each type of hepatoma cells. These results indicate that these two types of hepatoma cells bear two kinds of antigenic determinants, one kind unique to each hepatoma and the other kind cross-reactive with the other hepatoma cells.(ABSTRACT TRUNCATED AT 250 WORDS)